Tag: Diabetes: Type II
Fenofibrate May Reduce CVD in Patients With DM, Dyslipidemia
No reduction in primary outcome for 4,644 ACCORD participants followed for median of 9.7 years
Metformin Tied to Better Clinical Outcomes in CKD, CHF, CLD
Reduced all-cause death for chronic kidney disease, congestive heart failure, chronic liver disease
ACP Updates Recommendations for Oral Medications in T2DM
Recs serve as update to 2012 American College of Physicians guideline
Lactobacillus Supplement Doesn’t Impact HbA1c in Type 2 Diabetes
Patients receiving highest dose of L. reuteri have increases in insulin sensitivity index versus baseline
Luseogliflozin Effective for T2DM With Low-Carb, High-Carb Diet
Similar efficacy when meals contain 40 to 55 percent total energy from carbohydrate
Postprandial Hyperglycemia Linked to CVD Incidence in T2DM
Association with cardiovascular disease and mortality is independent of mean HbA1c level
More Years Lost for Whites Versus South Asians, Blacks With T2DM
Older South Asians with diabetes have longer life expectancy than South Asians without diabetes
Chronic Hepatitis B Prevalence Higher in Those With T2DM
Findings based on comparison to adult-onset autoimmune diabetes, controls
Lowest Glucose Variability for Insulin + GLP-1 RA in T2DM
Lowest glucose variability, hypoglycemia for basal insulin + GLP-1 receptor agonist regimen
Long-Term DPP4-Inhibitor Use Not Tied to Fracture Risk in T2DM
No increase in risk of any fracture, osteoporotic or hip fractures with continuous long-term use